- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01668693
ERA Test in Patients With Recurrent Implantation Failure (ERA)
The Endometrial Receptivity Array (ERA) as Diagnosis and Personalized Embryo Transfer (pET) as Treatment in Patients With Receptive Implantation Failure (RIF).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Intervention(s): Endometrial sampling, either at LH+7 in a natural cycle or after 5 days of progesterone in a hormonal replacement cycle (HRT) and personalized embryo transfer (pET) on the designated day guided by the ERA prediction.
Repeated implantation failure (RIF) is an unsolved not well characterized major cause of infertility in otherwise healthy women. Although various definitions of RIF exist, the clinical community agrees that after failure of three IVF cycles, in which one to two morphologically high-grade embryos have been transferred, special protocols must be enforced, although no hard data from RCTs demonstrates that any of the current approaches in RIF have a significant clinical value .
Based on the large amount of information generated about the regulation and deregulation of the genes implicated in the endometrial window of receptivity (WOR), our group has developed a molecular diagnostic tool based on the specific transcriptomic signature that identifies the receptive endometrium at LH+7 in a natural cycle or on day 5 of progesterone impregnation (P+5) after proper estradiol priming in a hormonal replacement therapy (HRT) cycle. The endometrial receptivity array (ERA) consists of a customized array containing 238 genes differentially expressed that is coupled to a computational predictor able to diagnose the personalized endometrial WOI of a given patient, regardless of its histological appearance. The accuracy of the diagnostic tool ERA has been demonstrated to be superior to endometrial histology and results are completely reproducible 29 to 40 months later.
Compelling evidence indicates the existence of an endometrial receptivity alteration in patients with RIF.
The aim of this study is to demonstrate the diagnostic efficiency of the ERA test in RIF patients by identifying putative alterations related to the displacement of their personalized window of receptivity, and the therapeutic implications through personalization of the day of embryo transfer (pET), following the diagnosis obtained by this molecular diagnostic tool. An endometrial biopsy on day LH+7 in a natural cycle or on day P+5 in an HRT cycle and ERA diagnosis of receptive or non-receptive is informed. In receptive cases, embryo transfer (ET) will be performed in subsequent cycles on the indicated day. In non-receptive ERA, the test is to be repeated on the dayindicated by the predictor, and personalized ET guided in subsequent cycles according to ERA diagnosis.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Carlos Simon, MD PhD
- Phone Number: +34963050900
- Email: carlos.simon@ivi.es
Study Contact Backup
- Name: Carlos Gómez, Ma
- Phone Number: +34670506469
- Email: carlos.gomez@igenomix.com
Study Locations
-
-
VAencia
-
Valencia, VAencia, Spain
- Recruiting
- IVI
-
Contact:
- Carlos Simon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women ≤38 years old
- Normal ovarian reserve
- FSH <8mIU/mL
- Cycle with ≥6 MII oocytes/oocyte retrieval
- ≥3 implantation failures in previous IVF/ICSI cycles with transfer of atleast two good quality embryos in each cycle Inclusion Criteria for ovum donation recipients
- ≥3 implantation failures with transfer of atleast two good quality embryos in each cycle
- Endometrial thickness ≥ 6 mm
- Trilaminar pattern after proper progesterone priming
Exclusion Criteria:
- Existance of hydrosalpinx
- Atrophic endometrium < 6 mm
- Previous ectopic or uterine miscarriages
- Presence of myomas or polyps
- Previous embryo transfer with high difficulty and/or bleeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: RIF ERA Receptive 1
With the "receptive" results from the first Endometrial Receptivity Array (ERA), the patients will undergo embryo transfer on Day 5 of Progesterone administration in the cycle following the ERA diagnosis.
|
The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group "Receptive" or "Non Receptive" and to predict the number of days of Progesterone administration necesary to obtain the "Receptive" prediction.
When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
|
Experimental: RIF ERA Non Receptive
The "Non Receptive" results of the ERA diagnotic tool will indicate how many more days of Progesterone are necesary in order to obtain the "Receptive" daignosis.
A second ERA will take place to confirm receptivity and in the following cycle, the personalized embryo transfer will take place on the day predicted by this diagnostic tool.
|
The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group "Receptive" or "Non Receptive" and to predict the number of days of Progesterone administration necesary to obtain the "Receptive" prediction.
When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
A second ERA will be performed to confirm receptivity after further administration of Progesterone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Detection of the Receptive or Non Receptive endometrial status according to the ERA test.
Time Frame: 1 months
|
1 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pregnancy
Time Frame: 6 weeks
|
6 weeks
|
Implantation
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Carlos Simón, MD PhD, ºIGENOMIX / IVI Valencia
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 0600-E-905-JH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Repetitive Implantation Failure
-
Instituto BernabeuCompletedImplantation FailureSpain
-
AZ Jan Palfijn GentOnze Lieve Vrouw HospitalCompleted
-
Ain Shams UniversityCompletedRepeated Implantation FailureEgypt
-
ZhangTaoUnknown
-
An Sinh HospitalVietnam National UniversityCompletedRepeated Implantation FailureVietnam
-
Shanghai First Maternity and Infant HospitalUnknownRepeated Implantation Failure
-
Assaf-Harofeh Medical CenterUnknownRepeated Implantation Failure
-
Tanta UniversityMansoura University; Benha UniversityRecruitingRepeated Implantation Failure | ICSI Failure | uNatural Killer CellsEgypt
-
University Hospital, GhentCenter for Microbial Ecology and Technology - Ghent UniversityCompletedRepeated Implantation Failure | Normal FertileBelgium
-
Huazhong University of Science and TechnologyRecruitingRepeated Implantation FailureChina
Clinical Trials on ERA (Endometrial Receptivity Array)
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompleted
-
Pirogov Russian National Research Medical UniversityCompletedEndometrial Cancer | Endometrial Hyperplasia Without Atypia | Postmenopause | Peripheral Blood Mononuclear Cells | Endometrial Hyperplasia With Atypia | Estrogen Receptor | Progesterone Receptor
-
Fundación IVIInstituto Valenciano de Infertilidad, IVI VALENCIARecruiting